Literature DB >> 16513685

Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.

Jörg Spiegel1, Dirk Hellwig, Marc-Oliver Möllers, Stefanie Behnke, Wolfgang Jost, Klaus Fassbender, Samuel Samnick, Ulrich Dillmann, Georg Becker, Carl-Martin Kirsch.   

Abstract

Hyperechogenic signal of substantia nigra (SN) in transcranial sonography (TCS) and reduced striatal uptake in FP-CIT SPECT are common findings in idiopathic Parkinson's disease (PD). But so far it is unknown whether the extent of SN hyperechogenicity represents a correlate for the degeneration of presynaptic dopaminergic neurons in PD. We performed TCS and 123I-labelled N-(3-fluoropropyl)-2ss-carbomethoxy-3ss-(4-iodophenyl)nortropane ([123I]FP-CIT) SPECT in 53 patients with PD. Striatal FP-CIT uptake was quantified by measuring the striatal/posterior lobe binding of [123I]FP-CIT. SN echogenicity was quantified by planimetric measurement of the maximum extension of hyperechogenic signals. We found no correlation between striatal FP-CIT uptake and echogenicity of the SN, neither contralateral to the clinically more affected body side (r = +0.08, P = 0.57; Pearson's correlation) nor ipsilateral (r = +0.01; P = 0.92). Our data show that the extent of SN hyperechogenicity does not correlate with the degeneration of presynaptic dopaminergic nerve terminals. Obviously SN hyperechogenicity and degeneration of presynaptic dopaminergic nerve terminals exist independently from each other and may be based on different pathomechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513685     DOI: 10.1093/brain/awl042

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

Review 1.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 2.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

3.  Transcranial sonography in movement disorders: an interesting tool for diagnostic perspectives.

Authors:  E Sanzaro; F Iemolo
Journal:  Neurol Sci       Date:  2015-12-09       Impact factor: 3.307

4.  Rapid-onset dystonia-parkinsonism: case report.

Authors:  Marina Svetel; Laurie J Ozelius; Amber Buckley; Katja Lohmann; Lela Brajković; Christine Klein; Vladimir S Kostić
Journal:  J Neurol       Date:  2010-03       Impact factor: 4.849

Review 5.  Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.

Authors:  Andrea Pilotto; Rezzak Yilmaz; Daniela Berg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 6.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

7.  Hand function is impaired in healthy older adults at risk of Parkinson's disease.

Authors:  Gabrielle Todd; Miranda Haberfield; Patrick L Faulkner; Caroline Rae; Michael Hayes; Robert A Wilcox; Janet L Taylor; Simon C Gandevia; Jana Godau; Daniela Berg; Olivier Piguet; Kay L Double
Journal:  J Neural Transm (Vienna)       Date:  2014-05-03       Impact factor: 3.575

8.  Transcranial sonography in spinocerebellar ataxia type 2.

Authors:  Milija Mijajlović; Natasa Dragasević; Elka Stefanova; Igor Petrović; Marina Svetel; Vladimir S Kostić
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

9.  Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control.

Authors:  Hee Young Shin; Eun Youn Joo; Seong Tae Kim; Hun-Jong Dhong; Jin Whan Cho
Journal:  Neurol Sci       Date:  2012-07-28       Impact factor: 3.307

Review 10.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.